The pharmaceutical manufacturing industry grew by nearly 13% in the first two months, and it is expected to continue to develop rapidly throughout the year

[Pharmaceutical Network Market Analysis] In recent years, China's pharmaceutical consumption demand has further expanded, and the pharmaceutical market has achieved rapid development
.

The industry predicts that with the continuous growth of market demand, the future prospects of the pharmaceutical industry are promising
.

So how will the pharmaceutical industry develop in 2022? The data shows that from January to February 2022, the added value of China's pharmaceutical manufacturing industry will maintain double-digit growth, with a year-on-year increase of nearly 13%, a growth rate higher than the national industry 5.
4%, and also higher than the growth rate of most major manufacturing industries
.

At the same time, exports maintained rapid growth, and the export delivery value increased by more than 24% year-on-year, which was 7.
4% higher than that of the national industry
.

In addition, data shows that from January to February 2022, the operating income of China's pharmaceutical manufacturing industry will increase by 2.
3% year-on-year; total profits will decrease by 17.
6% year-on-year
.

Analysts pointed out that due to the continued high level of profits in 2021, the prices of vaccines and other core profit growth points in 2021 will be greatly reduced this year, which will affect the growth of pharmaceutical manufacturing profits throughout the year
.

 　　It is understood that in 2021, the operating income of China's pharmaceutical manufacturing industry will increase by nearly 18% year-on-year to 2,928.
85 billion yuan
.

In 2021, the export delivery value of the pharmaceutical manufacturing industry will increase by nearly 65% ​​year-on-year to 340.
5 billion yuan, and the growth rate will increase by 28%
.

 　　With the increase in pharmaceutical operating income, the profitability of the pharmaceutical industry has also continued to improve.
In 2021, the total profit of China's pharmaceutical manufacturing industry will increase by nearly 79% year-on-year, reaching 627.
14 billion yuan
.

 　　The pharmaceutical industry is an important part of China's national economy, closely related to people's health, and an important industry that is related to the construction of a harmonious society
.

In recent years, in order to promote the development of the pharmaceutical industry, China has issued a series of industrial policies
.

For example, the "14th Five-Year Plan for the Development of the Pharmaceutical Industry", "Notice on the Implementation Plan for Promoting the High-Quality Development of the API Industry", "Action Plan to Make the Pharmaceutical Industry Bigger and Stronger (2021-2023)", "About Supporting the Pharmaceutical Industry" Policies such as the Notice on Several Measures for Industrial Development have continuously promoted the development of the pharmaceutical industry
.

 　　Driven by favorable policies, the pharmaceutical industry will continue to develop rapidly in 2022
.

According to data forecasts, the scale of China's pharmaceutical market is expected to reach 2,231.
1 billion yuan in 2022
.

 　　In 2022, the operating income of China's pharmaceutical industry may exceed 3 trillion yuan, and the total profit will approach 700 billion yuan
.

Thanks to the continuous boom in the pharmaceutical industry, it is expected that in 2022, China's new pharmaceutical-related enterprises will increase by 19.
2% year-on-year, reaching 298,000
.

 　　In recent years, the overall development of China's pharmaceutical industry has been good, but some analysts have pointed out that there are some problems that need urgent breakthroughs in the development and transformation of new drugs and the accessibility of patients
.

For example, the effectiveness of new drug approval is still limited by the number of personnel and lack of experience, and the pressure on the budget is not conducive to the stability of the team and the improvement of professionalism
.

 　　For the development of the pharmaceutical industry, the person suggested that the introduction of expert resources to support the training of drug reviewers, the implementation of the expert advisory committee mechanism, the establishment of overseas review expert consultation channels; the optimization of recruitment rules, and the reasonable determination of the negotiated price of medical insurance; full consideration should be given to innovative drugs Drugs are in different life cycles, and certain price reduction protections are given to protect the enthusiasm for innovation
.

"Testing and Calibration of Dry Body Temperature Calibrators" is about to be broadcast, welcome to sign up Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to anyone
.